CD274 and non-small cell lung carcinoma: As durvalumab (an anti-PD-L1 antibody) has been reported to be effective in patients with LA-NSCLC after concurrent CRT, our immune signature may have great potential for identifying patients who are suitable for subsequent immunotherapy, or at least provide a promising reference for the screening of the useful biomarker predicting the prognosis of LA-NSCLC receiving immunotherapy.